Welcome to the WittKieffer Global Life Sciences Newsletter, a quarterly publication that shares industry-leading trends, expert insights, and curated content from our worldwide network of consultants.
At WittKieffer, we partner with organizations committed to enhancing Quality of Life, notably including life sciences companies at the forefront of innovation in therapies, diagnostics, tools, devices, and services. Our comprehensive suite of services — executive search, leadership advisory, and interim leadership — is meticulously designed to cultivate impactful leadership that propels growth and value creation.
|
|
|
OBSERVATIONS FROM RECENT INDUSTRY CONFERENCES
|
Jefferies 2025 Global Healthcare Conference, New York, June 3-5, 2025
|
- Walking the Tightrope: Many companies find themselves walking a fine line between capital scarcity (both private and public) and the need to prove commercial viability. Investors are prioritizing risk mitigation, which is driving companies to pursue partnerships. Those that demonstrate commercial revenue, even if their innovations are not highly disruptive, are being rewarded. Companies will be held to clear and measurable metrics of commercial progress.
- Clear Market Superiority Attracts Attention: Significant improvements in efficacy and/or patient value attract capital, partners, and talent. Some of the popular therapeutic areas of focus include rare diseases, cardiovascular, metabolic, and ophthalmology. While oncology remains of interest, companies are looking for more cost-effective technologies and innovative pathways to develop more potent and targeted therapies. The CNS area continues to be challenging to develop due to higher costs and risks.
- Leadership Implications: There is an increased focus on hiring business development and strategy roles, whether full-time, interim, or on-demand, to effectively develop and manage these partnerships. Demand for proven Chief Commercial Officers and Chief Medical Officers is on the rise.
|
Swiss Biotech Day, Basel, May 5-6, 2025
|
- Global Strategic Alliances in Focus: Large pharma companies are eager to broaden their access to both traditional and non-traditional innovation areas, moving beyond therapeutic areas like immunology, rare diseases, and neurology to explore novel areas such as immuno-aging. Corporate venture capital arms of large pharma companies are active in the comparatively stable Swiss biotech market, while Swiss-based biotech companies are forming strategic alliances with global pharma firms, such as Takeda, Viatris, Eli Lilly, and Innoviva.
- China’s Growing Presence in Europe: Conference participants expressed a positive outlook on China, highlighting the speed and quality of its development. Chinese engagement with European biopharma companies appears to be increasingly active, with a focus on both partnering and investing. In comparison to their U.S. counterparts, European investors and companies seem more receptive to such engagement.
- The Promise and Uncertainty of AI: Despite almost universal recognition of AI’s potential to aid in drug discovery and commercialization, through pattern recognition and analytics, high levels of uncertainty remain regarding the cost and, consequently, the ultimate ROI of AI deployment.
- Leadership Implications: Proficiency in engaging in global business development and forging strategic alliances will be paramount, driving demand for proven business development leaders. Growth in the Swiss contract development and manufacturing organization (CDMO) sector is accompanying a robust and growing Swiss biotech market.
|
Chief Medical Officer Summit 360, Boston, April 7-8, 2025
|
- Investor Priorities in Risk Mitigation: Investors and their portfolio companies are prioritizing sustainable business models, risk mitigation strategies, and efficient capital use.
- Increasing Protocol Complexity: Protocol complexity is on the rise, with data points reportedly increasing by 4x in Phase 3 trials over the past decade. However, AI offers a promising solution and potential to increase efficiency. Additionally, decentralized trials and patient-informed trials have the potential to deliver efficiency gains through accelerated timelines, lower costs, and improved data quality.
- Leadership Implications: The biopharma industry is experiencing a significant shift toward flexible leadership models, with interim and on-demand Chief Medical Officers becoming increasingly central to strategic growth and capital efficiency. These leadership approaches offer compelling advantages for organizations navigating capital constraints while seeking specialized expertise. Interim medical leadership creates strategic value by closing clinical voice gaps, aligning with company growth trajectories, elevating development strategy, and building multidisciplinary excellence.
|
|
|
|
|
Accelerating Biopharma Growth through Strategic Interim Medical and Clinical Leadership
|
|
|
|
Animal Health, Nutrition & Technology Innovation USA, Boston, June 11-13, 2025
|
- Continued Growth and Innovation: The animal health sector is on a robust growth trajectory, with projected market value of $50-$60 billion by 2030, fueled by innovations in blockbuster drugs and new delivery models, such as online purchasing and at-home pet care. Companion animals dominate the US market, while the consolidation of vet clinics and the rise of generic drugs are reshaping the industry landscape. Additionally, sustainability and AI-driven drug design are paving the way for a more responsive and innovative market.
- Leadership Implications: As the industry evolves, so must its leaders. The current market environment demands transformative leaders who are innovative, resilient, and adaptable, focusing on forging win-win partnerships, driving change, and accelerating value creation. Experience in developing growth and performance playbooks, along with agility in evolving business models through digital technology, data, and scientific advancements, is essential for impactful leadership.
|
|
|
|
Coming Up: Where to Meet Us
|
| Dates |
Event Name |
Location |
August 5-7, 2025
|
LEAP HR: Life Sciences East 2025 |
Boston, U.S. |
| September 16-17, 2025 |
LSX USA Congress |
Boston, U.S. |
| September 25-26, 2025 |
CHAM 2025 |
Chamonix, France |
| November 18-20, 2025 |
Jefferies Healthcare Conference |
London, U.K. |
| November 20-21, 2025 |
London Vet Show |
London, U.K. |
|
ADVANCING IMPACTFUL LEADERSHIP IN LIFE SCIENCES
|
Executive Leadership
Chief Technology Officer at a Leading Global CDMO Specializing in End-To-End Solutions for the Pharma and Chemical Industries
|
Need: Following significant expansion of a key U.S. manufacturing site, a global CDMO faced a multitude of obstacles, including equipment failures and insufficient preventative maintenance processes. To overcome these hurdles and drive rapid scaling and operational excellence, the company urgently needed a strategic leader.
Solution: WittKieffer launched a targeted national executive search across the U.S., ultimately securing a highly qualified Chief Technology Officer. This industry veteran brought over 25 years of API manufacturing experience and a proven track record of building and leading high-performing teams in process development, validation, and commercial production across bench, pilot plant, and commercial scales.
|
Interim & On-Demand Leadership
MLR Pilot Execution Leadership for Innovation Program at Publicly Traded Mid-Sized Biotech Company
|
Need: A mid-sized public biotech company aimed to revolutionize its medical, legal, and regulatory (MLR) processes to dramatically boost volume throughput and operational efficiency. To accomplish this ambitious goal, the company required strategic execution support and proven leadership to implement and help drive transformative change with the internal and external team.
Solution: WittKieffer identified and engaged two seasoned commercial executives with proven track records of driving successful MLR transformations and executions at large pharma organizations. These on-demand leaders promptly helped implement an initial pilot and developed training and communications materials, then rapidly scaled out processes within an impressive 4-month project timeline, delivering tangible results and setting the stage for sustained operational excellence and expansion of the program.
|
Leadership Advisory
Assessing Talent as a Key Driver of Value Creation and Sustained Growth
|
Need: A venture capital-backed biotech company was facing a critical inflection point, preparing to launch its first commercial product and enter a new fundraising round. Concerns arose about whether the current CEO was the right leader to navigate these pivotal events, inspire the team, and attract additional high-caliber talent. The board sought to understand the CEO’s strengths and identify key risk areas, particularly in relation to commercialization and fundraising.
Solution: WittKieffer implemented a Leadership Catalyst Assessment combined with a 360-degree feedback process. This involved creating a CEO scorecard to outline essential deliverables for value creation, conducting in-depth assessments, and leading a comprehensive feedback process with the leadership team. The outcome was a strategic alignment of leadership capabilities with the company’s growth milestones, enabling the CEO to make substantive developmental progress and impactfully lead the firm forward.
|
|
|
Our interactive infographic, Pharma Services: Accelerating Value Creation, explores how rapid technological and market changes are reshaping the pharma services sector. From specialized partnerships to therapeutic innovations like GLP-1, we examine key trends, particularly in technology-driven solutions, modernizing drug development and commercialization.
Why It Matters: Through understanding industry dynamics and investor priorities, it is possible to better identify experienced advisors and dynamic executives who can accelerate value creation, navigate the complexities of scaling operations, meet investor expectations, and drive sustained growth.
|
|
|
RECENT WITTKIEFFER PUBLICATIONS
|
Recent changes in the US administration and FDA have created significant uncertainty in the biotech sector, impacting global markets and investor confidence. To gain insights, we spoke with several Chief Medical Officers across Europe about the challenges and emerging opportunities in this shifting landscape.
Why It Matters: European biotech leaders are seeking to adapt their leadership approaches during this period of potential market recalibration by navigating funding challenges, capitalizing on shifting talent migration patterns, and strengthening regional regulatory collaboration.
|
In this Converge Cast episode, Jason Hawbecker, SVP and Head of External Growth & Innovation at Biogen, discusses how the company is embracing innovation beyond scientific advancement and explains Biogen’s approach to “meeting patients where they are — physically or digitally” through technologies, new service models, AI chatbots, and diverse partnerships.
Why It Matters: The discussion reveals how forward-thinking organizations are transforming healthcare by combining technology, partnerships, and patient-centered strategies to deliver greater impact, highlighting that true innovation in healthcare requires looking beyond traditional metrics to focus on improving patients’ everyday experiences.
|
Drawing on WittKieffer’s extensive experience across the biomedical innovation ecosystem and insights gathered through conversations with tech transfer leaders at Imperial College London, the University of St Andrews, and the University of Cambridge, this article explores the evolution, current opportunities, and pressing challenges within the UK tech transfer landscape.
Why It Matters: UK’s tech transfer and the commercialization of foundational research have made tremendous progress and become integral to the UK’s innovation ecosystem. To drive strategic evolution from an incubator economy to an innovation powerhouse, the UK now needs a comprehensive talent strategy that addresses structural challenges and develops domestic talent pipelines.
|
A high-performing executive team is a significant organizational asset, accelerating execution by improving both strategic and operational decision-making. However, all too often, many executive teams struggle to achieve true effectiveness, let alone high performance. The good news is that CEOs can take proactive steps to foster alignment and drive their executive teams towards peak performance.
Why it Matters: The key to building and sustaining a high-performing executive team lies not just in assembling skilled individuals, but in mastering the nuances of team dynamics. By doing so, CEOs can unlock their executive team’s full potential, leading to better outcomes and sustained organizational success.
|
|
|
WittKieffer Welcomes Virginie Lleu, Senior Partner in Global Life Sciences, to Lead New Paris Office
|
Virginie Lleu, a Senior Partner in WittKieffer’s Global Life Sciences Practice, brings her extensive expertise to our newly established Paris office. With a background in psychology and over two decades of experience as a trusted talent advisor, Virginie has been instrumental in driving the growth and development of companies and organizations within the healthcare and life sciences sectors. Her approach is deeply rooted in strong values and ethics, fostering open collaboration with clients to identify leaders who align perfectly with their strategic goals.
Joining Philippe Arnal, Managing Director, in Paris, Virginie is part of a purpose-built European team comprising more than a dozen members. Together, they are dedicated to helping life sciences clients in France and other European countries navigate business opportunities and challenges through the lens of leadership.
Connect with Virginie Lleu on LinkedIn
vlleu@wittkieffer.com
|
|
|
Learn more about WittKieffer and our full suite of solutions.
|
|
|
|
